AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Indivior PLC

Report Publication Announcement Aug 30, 2017

4923_rns_2017-08-30_9624f235-ef04-490c-b49b-86361b966aa1.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1613P

Indivior PLC

30 August 2017

Indivior's CEO to Participate in Morgan Stanley's 15th Annual Global Healthcare Conference on September 11th

Slough, UK and Richmond, VA, August 30th, 2017 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, CEO, will participate in Morgan Stanley's 15th Annual Global Healthcare Conference on September 11th, 2017, at 8:45 a.m. local time, in New York City. Mark Crossley, CFO, and Jason Thompson, VP of Investor Relations, will also participate. Thaxter will discuss Indivior's business and outlook. His remarks will be webcast live and the broadcast will be available on the "Investors" section of Indivior's website (www.indivior.com). If you plan on listening to the live webcast please allow sufficient time to register and download any audio software required to access the discussion.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: +1 804-423-8916 or [email protected]

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCOKCDPFBKKDFB

Talk to a Data Expert

Have a question? We'll get back to you promptly.